#United States #New York #Levi & Korsinsky #Iovance Biotherapeutics #IOVA

Important Notification for Investors in Iovance Biotherapeutics

Levi & Korsinsky, LLP is reaching out to investors of Iovance Biotherapeutics, Inc. (NASDAQ: IOVA) regarding a significant class action lawsuit that may have implications for your investments. If you have been affected by alleged securities fraud occurring within the timeframe of May 9, 2024, to May 8, 2025, it is crucial that you act before the approaching deadline of July 14, 2025.

Class Action Details

The lawsuit indicates that investors were misled by the company’s management, which provided overly optimistic statements about Iovance's growth potential while concealing severe operational deficiencies. Specifically, the lawsuit highlights that Iovance was not adequately prepared to meet the existing demand for its treatments. Investors might have suffered significant financial losses as a result.

On July 25, 2024, Iovance disclosed its financial performance for the second quarter of the fiscal year 2024. Alarmingly, the company lowered its revenue forecast for the entire fiscal year. Key reasons for this unfortunate development included:
Scheduled Maintenance: The iCTC’s necessary annual maintenance, which took place in December, led to a substantial reduction in capacity for about a month.
Sluggish Sales: Lower-than-expected sales of Proleukin contributed to the financial downturn.
* Variable Treatment Pace: The speed at which affiliated treatment centers began patient treatments was inconsistent.

This series of missteps caused the company's stock to plummet from a closing price of $3.17 per share on May 8, 2025, to $1.75 per share the following day—a staggering drop of approximately 44.8% in just 24 hours.

Next Steps for Investors

If you experienced a loss during the specified period as an Iovance investor, you have the legal right to seek recourse. It is essential to submit your request to the court to be designated as a lead plaintiff by July 14, 2025. However, the opportunity to receive compensation does not require you to take on this role.

No Cost to Participate

Investors should note that participating in this class action could entitle you to compensation without any upfront costs or fees. This is a no-obligation process designed to assist affected shareholders in regaining their losses.

Why Levi & Korsinsky?

With over two decades of experience, Levi & Korsinsky, LLP has reclaimed hundreds of millions for shareholders through its extensive knowledge of complex securities litigation. The firm has consistently demonstrated success in high-stakes cases, earning a reputation as one of the top securities litigation firms in the United States according to ISS Securities Class Action Services.

Contact Information

For more inquiries regarding this lawsuit or to discuss your rights, please contact:
Joseph E. Levi, Esq.
Ed Korsinsky, Esq.
Levi & Korsinsky, LLP
33 Whitehall Street, 17th Floor
New York, NY 10004
Email: [email protected]
Phone: (212) 363-7500

This is a crucial chance for Iovance investors to ensure their rights are protected. Don't miss the opportunity to be part of this transformative legal action. Act now to safeguard your financial interests.